Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alvotech Attacks AbbVie Over Adalimumab

Launches US Legal Challenge Over Humira Patent ‘Monopoly’

Executive Summary

Alvotech has launched a US legal challenge over intellectual property around AbbVie’s Humira, claiming that the company enjoys a “wrongful monopoly” on the top-selling arthritis treatment for which the biosimilars company is developing a high-concentration adalimumab rival.

You may also be interested in...

AbbVie Humira Lawsuit Withstands Alvotech Attack

Alvotech has failed in an attempt to dismiss US litigation initiated by AbbVie over Alvotech’s AVT02 proposed rival to higher-strength Humira. The company is expecting an FDA decision on the adalimumab biosimilar this month.

Alvotech Welcomes Stelara Biosimilar Into Phase III Development

Alvotech has announced two studies running in parallel for the firm’s AVT04 ustekinumab biosimilar referencing Janssen’s $7.7bn Stelara treatment for autoimmune diseases, including a Phase III comparative study.

Alvotech Adalimumab Biosimilar Switching Study Hits Key Date

Alvotech underlined that it could “save US consumers and taxpayers billions annually,” after hitting a key landmark in its Phase III switching study for its high concentration 100mg/ml biosimilar Humira product.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts